FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Desmarais John M 		2. Issuer Name and Ticker or Trading Symbol

BioRestorative Therapies, Inc. [ BRTX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

230 PARK AVENUE 		3. Date of Earliest Transaction (MM/DD/YYYY)

11/17/2017
(Street)

NEW YORK, NY 10169
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock                  493398   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option   $4.4                      (1) 12/1/2025   Common Stock   15000     15000   D    
Warrant   $5   11/17/2017     D         125000    12/17/2015   11/17/2020   Common Stock   125000     (5) 0   D    
Warrant   $4   11/17/2017     A      125000       12/17/2015   11/17/2020   Common Stock   125000     (5) 125000   D    
Warrant   $5   11/17/2017     D         250000    3/18/2016   3/18/2021   Common Stock   250000     (5) 0   D    
Warrant   $4   11/17/2017     A      250000       3/18/2016   3/18/2021   Common Stock   250000     (5) 250000   D    
Warrant   $4.5   11/17/2017     D         444444    3/18/2016   12/31/2018   Common Stock   444444     (5) 0   D    
Warrant   $4   11/17/2017     A      444444       3/18/2016   12/31/2018   Common Stock   444444     (5) 444444   D    
Warrant   $5   11/17/2017     D         400000    3/18/2016   12/31/2018   Common Stock   400000     (5) 0   D    
Warrant   $4   11/17/2017     A      400000       3/18/2016   12/31/2018   Common Stock   400000     (5) 400000   D    
Option   $3.73                      (2) 6/10/2026   Common Stock   35000     35000   D    
Warrant   $4                    6/30/2016   6/30/2021   Common Stock   40000     40000   I   (3) Trust  
Warrant   $4                    9/26/2016   9/26/2021   Common Stock   80000     80000   D    
Warrant   $4                    2/10/2017   2/10/2022   Common Stock   21731     21731   D    
Warrant   $4                    3/1/2017   3/1/2022   Common Stock   16667     16667   D    
Stock Option   $3.35                      (4) 6/23/2027   Common Stock   125000     125000   D    

Explanation of Responses:
(1)  The option vests to the extent of 5,000 shares on each of December 1, 2016, 2017 and 2018.
(2)  The option vests to the extent of 11,667 shares on each of June 10, 2016 and June 10, 2017, and 11,666 shares on June 10, 2018.
(3)  The warrant is held by a trust established by the Reporting Person for the benefit of his immediate family. The Reporting Person serves as a trustee of the trust.
(4)  The option is exercisable to the extent of 41,667 shares on each of June 23, 2017 and June 23, 2018, and 41,666 shares on June 23, 2019.
(5)  The reported transactions involved an amendment of an outstanding warrant resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant at a reduced exercise price.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Desmarais John M
230 PARK AVENUE
NEW YORK, NY 10169 		X X


Signatures
/s/ Fred Skolnik, by power of attorney, for John M. Desmarais 11/17/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.